Health

Global Heart Hub and the Global Coalition on Aging launch a Global Position Paper on Heart Valve Disease (HVD) and the Healthy Aging Agenda

The Global Coalition on Aging (GCOA) and the Global Heart Hub (GHH) have released the global position paper “Heart Valve Disease: Harnessing Innovation to Save Lives, Mitigate Costs, and Advance the Healthy Aging Agenda”, which builds on a December 2022 roundtable of cross-sector experts and examines how behavior and policy change can best address HVD. “The impacts […]

thaipr.net

24 มี.ค. 66

DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM

Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™. The first patient was screened and dosed at the Australian-based Peter MacCallum Cancer Centre. This multicenter international trial, evaluating a radioligand theranostic pair will…

thaipr.net

23 มี.ค. 66

FDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health

Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world’s population – Picture is available at AP Images (http://www.apimages.com) – Today, FDI World Dental Federation (FDI) called on governments and global health bodies to prioritise action against oral diseases, including through integrating oral health at the United Nations […]

thaipr.net

20 มี.ค. 66

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES]. SELUTION DeNovo is the largest […]

thaipr.net

16 มี.ค. 66

Servier’s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

Servier, a global pharmaceutical group, announced today that the Phase 3 INDIGO clinical trial investigating vorasidenib in monotherapy for patients with residual or recurrent IDH mutant low-grade glioma met its primary endpoint of progression free survival (PFS) and the key secondary endpoint of time to next intervention (TTNI). The results of the prespecified interim analysis […]

thaipr.net

15 มี.ค. 66
1 … 46 47 48 49 50 … 133

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.